Huld helped Revenio Group in developing their new asthma diagnosis product, Ventica.
Huld helped Revenio Group in developing their new asthma diagnosis product, Ventica. Ventica uses a novel non-invasive approach for identifying airway obstructions in even very young patients. It works by collecting respiration data from the patient while they are sleeping.
The measurements performed by Ventica are based on skin contact electrodes, which means that the signal integrity may be easily disrupted. Common causes are for instance the patient turning in bed, coughing or talking. It is also possible that an electrode becomes disconnected during the measurement.
All these disruptions needed to be detected by the algorithm and removed from the analysis data. During development, Huld also implemented a fast raw data parser in MATLAB for importing the raw data from the measurement hardware.
Revenio is a successful, globally operating health technology corporation. The focus of Revenio’s screening technology is on the early detection of Glaucoma, Diabetic Retinopathy and Macular Degeneration, and the monitoring of these diseases during the treatment process. Revenio Research in turn focuses on the commercialization of systems designed to help diagnose and plan the treatments for skin cancer and asthma. Revenio Group’s core business is to develop and commercialize efficient and easily adopted health tech devices especially for the detection of eye diseases that are significant to public health. The amount of eye diseases is rising rapidly due to the aging of the population.